Coronavirus (COVID-19) information for Dana-Farber patients & familiesLearn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request alive medical interpreter for a discussion about your care.
Menu
For Patients & Families
Nikhil Wagle博士(Nikhil Wagle, MD)是丹娜—法伯癌症研究所癌症精准医学中心(Center for Cancer Precision Medicine at Dana-Farber)的副主任兼博德研究所的准会员(Associate Member of the Broad Institute)。
丹娜—法伯癌症研究所(Dana-Farber Cancer Institute)的科研团队发现:经激素治疗过的转移性乳腺癌(metastatic breast cancer treated with hormone therapy0)在原始肿瘤以外获得人类表皮生长因子受体-2(human epidermal growth factor receptor 2 ,简称HER2)突变时,疗法会出现耐药性(treatment-resistant)。
“我们惊异于转移性条件下能够后天获得HER2突变(HER2 mutations)这一发现,这就建议了这些肿瘤会有所演化。” 本研究的资深作者Nikhil Wagle博士(Nikhil Wagle, MD)说道,该研究后